Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8207MR)

This product GTTS-WQ8207MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8207MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11650MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ6141MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ15218MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ4259MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ13108MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ1374MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ9823MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ8124MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW